Berra Yazar-Klosinski, Ph.D., the chief scientific officer of Lykos Therapeutics, provides scientific leadership for global research & development efforts to bring psychedelic products to target markets. She utilizes scientific background to nurture ideas from proof of concept through New Drug Application filing, most recently with MDMA-assisted therapy for treatment of PTSD. Dr. Yazar-Klosinski began working on the development of MDMA-assisted therapy when she joined MAPS in 2009 and has been with Lykos since its inception in 2014. Berra has developed a strong track record of success with the FDA, EMA and other regulatory agencies. Prior to Lykos, Dr. Yazar-Klosinski worked with Geron Corporation and Millennium Pharmaceuticals. She earned her B.S. in Biology with a minor in Drama from Stanford University and her Ph.D. in Molecular, Cell, and Developmental Biology from the University of California, Santa Cruz.
Executive Committee